Logo
x

Search

Subscribe Now

Lymphocytic Leukemia

AstraZeneca's Calquence (acalabrutinib) Receives the US FDA's Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia

AstraZeneca's Calquence (acalabrutinib) Receives the US FDA's Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia

  • August 14, 2019
AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic Leukemia #EHA2019

AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic Leukemia #EHA2019

  • June 17, 2019
Roche Reports Results of Venclexta/Venclyxto (venetoclax) in P-III CLL14 Study for Chronic Lymphocytic Leukemia #ASCO2019

Roche Reports Results of Venclexta/Venclyxto (venetoclax) in P-III CLL14 Study for Chronic Lymphocytic Leukemia #ASCO2019

  • June 5, 2019
Roche and AbbVie's Venclexta (venetoclax) + Gazyva (obinutuzumab) Receive FDA's Approval for Untreated Chronic Lymphocytic Leukemia

Roche and AbbVie's Venclexta (venetoclax) + Gazyva (obinutuzumab) Receive FDA's Approval for Untreated Chronic Lymphocytic Leukemi...

  • May 16, 2019
InnoCare Receives Approval to Initiate Clinical Evaluation of ICP-248 in Combination with Orelabrutinib for Treating Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China

    InnoCare Receives Approval to Initiate Clinical Evaluation of ICP-248 in Combination with Orelabrutinib for Treating Chronic Lymph...

    • March 13, 2024
    Merck Reports the Initiation of a Series of P-III Trials for Bomedemstat, Nemtabrutinib, MK-2870 and MK-5684 to Treat Solid Tumors

      Merck Reports the Initiation of a Series of P-III Trials for Bomedemstat, Nemtabrutinib, MK-2870 and MK-5684 to Treat Solid Tumors

      • January 8, 2024
      New Drug Designations - November 2023

        New Drug Designations - November 2023

        • December 27, 2023
        The US FDA Approves BeiGene’s Label Update for Brukinsa to Include Chronic Lymphocytic Leukemia

          The US FDA Approves BeiGene’s Label Update for Brukinsa to Include Chronic Lymphocytic Leukemia

          • December 25, 2023
          Eli Lilly’s Jaypirca Receives the US FDA Approval for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma ( CLL/SLL )

            Eli Lilly’s Jaypirca Receives the US FDA Approval for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma...

            • December 4, 2023
            BMS Reports the US FDA’s Acceptance of sBLA with Priority Review for Breyanzi (lisocabtagene maraleucel) to Treat Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

              BMS Reports the US FDA’s Acceptance of sBLA with Priority Review for Breyanzi (lisocabtagene maraleucel) to Treat Chronic Lymphocy...

              • November 10, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.